Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

M2699

Sigma-Aldrich

Marimastat

≥98% (HPLC), solid, MMP inhibitor

Synonyme(s) :

BB2516, (2S,3R)-N4-[(1S)-2,2-Dimethyl-1-[(methylamino)carbonyl] propyl]-N1,2-dihydroxy-3-(2-methylpropyl)butanediamide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C15H29N3O5
Numéro CAS:
154039-60-8
Poids moléculaire :
331.41
Numéro MDL:
MFCD00866242
Code UNSPSC :
12352200
ID de substance PubChem :
329817950
Nomenclature NACRES :
NA.77

product name

Marimastat, ≥98% (HPLC)

Niveau de qualité

100

Pureté

≥98% (HPLC)

Forme

solid

Solubilité

DMSO: ≥20 mg/mL

Conditions d'expédition

wet ice

Température de stockage

−20°C

Chaîne SMILES 

CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C

InChI

1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1

Clé InChI

OCSMOTCMPXTDND-OUAUKWLOSA-N

Informations sur le gène

Application

Marimastat has been used as an inhibitor of:
  • metalloproteinase 2/9 (MMP2/9), to study its effects on exercise-mediated interleukin-6 (IL-6) release in mice
  • metalloproteinase, to determine protease activity in Pseudomonas aeruginosa cultures
  • metalloproteinase 10 (MMP10), to study its effect on monoclonal antibody H3 binding to MMP10

Actions biochimiques/physiologiques

Marimastat is a broad spectrum matrix metalloprotease (MMP) inhibitor

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 6

1 of 6

TAPI-1 InSolution, ≥97%, inhibits MMPs and TACE

Sigma-Aldrich

579053

TAPI-1

Ecotin, E. coli A potent, broad range inhibitor of serine proteases.

Sigma-Aldrich

330200-M

Ecotin, E. coli

MMP-13 Substrate, Fluorogenic A quenched fluorescence substrate for MMP-13 (collagenase-3; kcat/Km = 1.09 x 10⁶ M⁻¹s⁻¹).

Millipore

444235-M

MMP-13 Substrate, Fluorogenic

D-(−)-Ribose suitable for cell culture, BioReagent

Sigma-Aldrich

R9629

D-(−)-Ribose

TAPI-0 ≥95% (HPLC)

Sigma-Aldrich

SML1292

TAPI-0

Varespladib ≥98% (HPLC)

Sigma-Aldrich

SML1100

Varespladib

Vincent E de Meijer et al.
PloS one, 5(6), e11256-e11256 (2010-07-02)
Liver fibrosis is characterized by excessive synthesis of extracellular matrix proteins, which prevails over their enzymatic degradation, primarily by matrix metalloproteinases (MMPs). The effect of pharmacological MMP inhibition on fibrogenesis, however, is largely unexplored. Inflammation is considered a prerequisite and
Aura D Urribarri et al.
Gut, 63(10), 1658-1667 (2014-01-18)
Polycystic liver diseases (PCLDs) are genetic disorders characterised by progressive bile duct dilatation and/or cyst development. Their pathogenesis is a consequence of hyperproliferation, hypersecretion and microRNA alterations in cholangiocytes. Here we evaluate the role of matrix metalloproteases (MMPs) in the
Timothy W Failes et al.
Chemistry (Weinheim an der Bergstrasse, Germany), 13(10), 2974-2982 (2006-12-16)
We report a potential means of selectively delivering matrix metalloproteinase (MMP) inhibitors to target tumour sites by use of a bioreductively activated Co(III) carrier system. The carrier, comprising a Co(III) complex of the tripodal ligand tris(methylpyridyl)amine (tpa), was investigated with
Victor A Levin et al.
Journal of neuro-oncology, 78(3), 295-302 (2006-04-26)
Because raised matrix metalloprotease (MMP) levels are associated with glioma invasion and angiogenesis, we tested the efficacy of marimastat (MT) an orally active drug that can reduce MMP levels, in patients with gliomas. A total of 162 patients with intracranial
M Ohshima et al.
Journal of dental research, 89(11), 1315-1321 (2010-08-27)
The underlying mechanism and the therapeutic regimen for the transition of reversible gingivitis to irreversible periodontitis are unclear. Since transforming growth factor (TGF)-β has been implicated in differentially regulated gene expression in gingival fibroblasts, we hypothesized that TGF-β signaling is
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique